Stock GALENA BIOPHARMA INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Galena Biopharma Inc Nasdaq

Equities

US3632561086

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Galena Biopharma Inc
Apr. 03 North American Morning Briefing : Powell Awaited -2- DJ
Mar. 28 SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
AQ
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
AQ
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
AQ
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
AQ
SELLAS Life Sciences : Material Event - Form 8-K
PU
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
AQ
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
AQ
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
AQ
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
AQ
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
AQ
GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia
AQ
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
AQ
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
AQ
SELLAS Life Sciences Announces Proposed Public Offering
AQ
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
AQ
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma
AQ
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
AQ
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
AQ
SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
AQ
SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLS Stock
  4. Stock
  5. News Galena Biopharma Inc
  6. Press Releases